Literature DB >> 28714273

β-Catenin regulation of farnesoid X receptor signaling and bile acid metabolism during murine cholestasis.

Michael D Thompson1, Akshata Moghe2, Pamela Cornuet3, Rebecca Marino3, Jianmin Tian3, Pengcheng Wang4, Xiaochao Ma4, Marc Abrams5, Joseph Locker3,6, Satdarshan P Monga2,3,6, Kari Nejak-Bowen3,6.   

Abstract

Cholestatic liver diseases result from impaired bile flow and are characterized by inflammation, atypical ductular proliferation, and fibrosis. The Wnt/β-catenin pathway plays a role in bile duct development, yet its role in cholestatic injury remains indeterminate. Liver-specific β-catenin knockout mice and wild-type littermates were subjected to cholestatic injury through bile duct ligation or short-term exposure to 3,5-diethoxycarbonyl-1,4-dihydrocollidine diet. Intriguingly, knockout mice exhibit a dramatic protection from liver injury, fibrosis, and atypical ductular proliferation, which coincides with significantly decreased total hepatic bile acids (BAs). This led to the discovery of a role for β-catenin in regulating BA synthesis and transport through regulation of farnesoid X receptor (FXR) activation. We show that β-catenin functions as both an inhibitor of nuclear translocation and a nuclear corepressor through formation of a physical complex with FXR. Loss of β-catenin expedited FXR nuclear localization and FXR/retinoic X receptor alpha association, culminating in small heterodimer protein promoter occupancy and activation in response to BA or FXR agonist. Conversely, accumulation of β-catenin sequesters FXR, thus inhibiting its activation. Finally, exogenous suppression of β-catenin expression during cholestatic injury reduces β-catenin/FXR complex activation of FXR to decrease total BA and alleviate hepatic injury.
CONCLUSION: We have identified an FXR/β-catenin interaction whose modulation through β-catenin suppression promotes FXR activation and decreases hepatic BAs, which may provide unique therapeutic opportunities in cholestatic liver diseases. (Hepatology 2018;67:955-971).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28714273      PMCID: PMC5771988          DOI: 10.1002/hep.29371

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  40 in total

1.  Liver-specific β-catenin knockout mice have bile canalicular abnormalities, bile secretory defect, and intrahepatic cholestasis.

Authors:  Tzu-Hsuan Yeh; Lindsay Krauland; Vijay Singh; Baobo Zou; Prathab Devaraj; Donna B Stolz; Jonathan Franks; Satdarshan P S Monga; Eizaburo Sasatomi; Jaideep Behari
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

2.  Pregnane X receptor is a target of farnesoid X receptor.

Authors:  Diana Jung; David J Mangelsdorf; Urs A Meyer
Journal:  J Biol Chem       Date:  2006-05-08       Impact factor: 5.157

3.  Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands.

Authors:  L B Moore; D J Parks; S A Jones; R K Bledsoe; T G Consler; J B Stimmel; B Goodwin; C Liddle; S G Blanchard; T M Willson; J L Collins; S A Kliewer
Journal:  J Biol Chem       Date:  2000-05-19       Impact factor: 5.157

4.  Wnt signaling regulates hepatobiliary repair following cholestatic liver injury in mice.

Authors:  Hirohisa Okabe; Jing Yang; Kyle Sylakowski; Mladen Yovchev; Yoshitaka Miyagawa; Shanmugam Nagarajan; Maria Chikina; Michael Thompson; Michael Oertel; Hideo Baba; Satdarshan P Monga; Kari Nichole Nejak-Bowen
Journal:  Hepatology       Date:  2016-09-26       Impact factor: 17.425

5.  Hepatic levels of bile acids in end-stage chronic cholestatic liver disease.

Authors:  S Fischer; U Beuers; U Spengler; F M Zwiebel; H G Koebe
Journal:  Clin Chim Acta       Date:  1996-07-30       Impact factor: 3.786

6.  A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected].

Authors:  Katayoon H Emami; Cu Nguyen; Hong Ma; Dae Hoon Kim; Kwang Won Jeong; Masakatsu Eguchi; Randall T Moon; Jia-Ling Teo; Se Woong Oh; Hak Yeop Kim; Sung Hwan Moon; Jong Ryul Ha; Michael Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-16       Impact factor: 11.205

7.  Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist.

Authors:  Sama I Sayin; Annika Wahlström; Jenny Felin; Sirkku Jäntti; Hanns-Ulrich Marschall; Krister Bamberg; Bo Angelin; Tuulia Hyötyläinen; Matej Orešič; Fredrik Bäckhed
Journal:  Cell Metab       Date:  2013-02-05       Impact factor: 27.287

8.  Loss of orphan receptor small heterodimer partner sensitizes mice to liver injury from obstructive cholestasis.

Authors:  Young Joo Park; Mohammed Qatanani; Steven S Chua; Jennifer L LaRey; Stacy A Johnson; Mitsuhiro Watanabe; David D Moore; Yoon Kwang Lee
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

9.  A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.

Authors:  Frederik Nevens; Pietro Andreone; Giuseppe Mazzella; Simone I Strasser; Christopher Bowlus; Pietro Invernizzi; Joost P H Drenth; Paul J Pockros; Jaroslaw Regula; Ulrich Beuers; Michael Trauner; David E Jones; Annarosa Floreani; Simon Hohenester; Velimir Luketic; Mitchell Shiffman; Karel J van Erpecum; Victor Vargas; Catherine Vincent; Gideon M Hirschfield; Hemant Shah; Bettina Hansen; Keith D Lindor; Hanns-Ulrich Marschall; Kris V Kowdley; Roya Hooshmand-Rad; Tonya Marmon; Shawn Sheeron; Richard Pencek; Leigh MacConell; Mark Pruzanski; David Shapiro
Journal:  N Engl J Med       Date:  2016-08-18       Impact factor: 91.245

10.  Decoding the role of the nuclear receptor SHP in regulating hepatic stellate cells and liver fibrogenesis.

Authors:  Sabrina Cipriani; Adriana Carino; Dario Masullo; Angela Zampella; Eleonora Distrutti; Stefano Fiorucci
Journal:  Sci Rep       Date:  2017-01-24       Impact factor: 4.379

View more
  22 in total

1.  Dual ablation of β- and γ-catenin: Critical regulators of junctions and their functions.

Authors:  Heather Francis; Lindsey Kennedy; Gianfranco Alpini
Journal:  Hepatology       Date:  2018-04-19       Impact factor: 17.425

Review 2.  Farnesoid X receptor: a potential therapeutic target in multiple organs.

Authors:  Chao Zhang; Zixuan Wang; Qingqing Feng; Wei-Dong Chen; Yan-Dong Wang
Journal:  Histol Histopathol       Date:  2021-01-04       Impact factor: 2.303

Review 3.  Role and Regulation of Wnt/β-Catenin in Hepatic Perivenous Zonation and Physiological Homeostasis.

Authors:  Chhavi Goel; Satdarshan P Monga; Kari Nejak-Bowen
Journal:  Am J Pathol       Date:  2022-01       Impact factor: 4.307

4.  Triazole-Based Inhibitors of the Wnt/β-Catenin Signaling Pathway Improve Glucose and Lipid Metabolisms in Diet-Induced Obese Mice.

Authors:  Obinna N Obianom; Yong Ai; Yingjun Li; Wei Yang; Dong Guo; Hong Yang; Srilatha Sakamuru; Menghang Xia; Fengtian Xue; Yan Shu
Journal:  J Med Chem       Date:  2019-01-10       Impact factor: 7.446

5.  Loss of hepatocyte β-catenin protects mice from experimental porphyria-associated liver injury.

Authors:  Harvinder Saggi; Dhiman Maitra; An Jiang; Rong Zhang; Pengcheng Wang; Pamela Cornuet; Sucha Singh; Joseph Locker; Xiaochao Ma; Harry Dailey; Marc Abrams; M Bishr Omary; Satdarshan P Monga; Kari Nejak-Bowen
Journal:  J Hepatol       Date:  2018-10-01       Impact factor: 25.083

6.  The Thyromimetic Sobetirome (GC-1) Alters Bile Acid Metabolism in a Mouse Model of Hepatic Cholestasis.

Authors:  Karis Kosar; Pamela Cornuet; Sucha Singh; Silvia Liu; Kari Nejak-Bowen
Journal:  Am J Pathol       Date:  2020-03-20       Impact factor: 4.307

7.  Wnt/β-Catenin Signaling Plays a Protective Role in the Mdr2 Knockout Murine Model of Cholestatic Liver Disease.

Authors:  Tirthadipa Pradhan-Sundd; Karis Kosar; Harvinder Saggi; Rong Zhang; Ravi Vats; Pamela Cornuet; Sydney Green; Sucha Singh; Gang Zeng; Prithu Sundd; Kari Nejak-Bowen
Journal:  Hepatology       Date:  2019-12-31       Impact factor: 17.425

8.  Hepatocyte and stellate cell deletion of liver fatty acid binding protein reveals distinct roles in fibrogenic injury.

Authors:  Elizabeth P Newberry; Yan Xie; Carlos Lodeiro; Roberto Solis; William Moritz; Susan Kennedy; Lauren Barron; Emily Onufer; Gianfranco Alpini; Tianhao Zhou; William S Blaner; Anping Chen; Nicholas O Davidson
Journal:  FASEB J       Date:  2018-12-21       Impact factor: 5.834

9.  Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP-305, a novel farnesoid X receptor agonist.

Authors:  Derek J Erstad; Christian T Farrar; Sarani Ghoshal; Ricard Masia; Diego S Ferreira; Yin-Ching Iris Chen; Ji-Kyung Choi; Lan Wei; Phillip A Waghorn; Nicholas J Rotile; Chuantao Tu; Katherine A Graham-O'Regan; Mozhdeh Sojoodi; Shen Li; Yang Li; Guogiang Wang; Kathleen E Corey; Yat Sun Or; Lijuan Jiang; Kenneth K Tanabe; Peter Caravan; Bryan C Fuchs
Journal:  Hepatol Commun       Date:  2018-05-21

Review 10.  Update on FXR Biology: Promising Therapeutic Target?

Authors:  Chang Yeob Han
Journal:  Int J Mol Sci       Date:  2018-07-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.